| Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). | |
| | |
MedLine Citation:
|
PMID: 11023927 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: This long-term, multicenter, randomized, double-blind, placebo-controlled, 2 x 2 factorial, angiographic trial evaluated the effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis in normocholesterolemic patients. METHODS AND RESULTS: There were a total of 460 patients: 230 received simvastatin and 230, a simvastatin placebo, and 229 received enalapril and 231, an enalapril placebo (some subjects received both drugs and some received a double placebo). Mean baseline measurements were as follows: cholesterol level, 5.20 mmol/L; triglyceride level, 1.82 mmol/L; HDL, 0.99 mmol/L; and LDL, 3.36 mmol/L. Average follow-up was 47.8 months. Changes in quantitative coronary angiographic measures between simvastatin and placebo, respectively, were as follows: mean diameters, -0.07 versus -0.14 mm (P:=0.004); minimum diameters, -0.09 versus -0.16 mm (P:=0. 0001); and percent diameter stenosis, 1.67% versus 3.83% (P:=0.0003). These benefits were not observed in patients on enalapril when compared with placebo. No additional benefits were seen in the group receiving both drugs. Simvastatin patients had less need for percutaneous transluminal coronary angioplasty (8 versus 21 events; P:=0.020), and fewer enalapril patients experienced the combined end point of death/myocardial infarction/stroke (16 versus 30; P:=0.043) than their respective placebo patients. CONCLUSIONS: This trial extends the observation of the beneficial angiographic effects of lipid-lowering therapy to normocholesterolemic patients. The implications of the neutral angiographic effects of angiotensin-converting enzyme inhibition are uncertain, but they deserve further investigation in light of the positive clinical benefits suggested here and seen elsewhere. |
| | |
Authors:
|
K K Teo; J R Burton; C E Buller; S Plante; D Catellier; W Tymchak; V Dzavik; D Taylor; S Yokoyama; T J Montague |
Related Documents
:
|
16510377 - Effects of fluvastatin treatment on lipid profile, c-reactive protein trend, and renal ... 18706277 - Statins and congestive heart failure. 14707887 - Self-monitoring of blood glucose significantly improves metabolic control in patients w... 17954357 - Beneficial effects of statin therapy on survival in hypertensive patients with acute my... 8306217 - Use of desmopressin acetate to reduce blood transfusion requirements during cardiac sur... 16361047 - Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Circulation Volume: 102 ISSN: 1524-4539 ISO Abbreviation: Circulation Publication Date: 2000 Oct |
Date Detail:
|
Created Date: 2000-10-26 Completed Date: 2000-11-07 Revised Date: 2007-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0147763 Medline TA: Circulation Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 1748-54 Citation Subset: IM |
Affiliation:
|
University of Alberta Hospitals, Edmonton, Alberta, Canada. teok@fhs.mcmaster.ca |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Aged Angiotensin-Converting Enzyme Inhibitors / therapeutic use* Anticholesteremic Agents / therapeutic use* Blood Pressure / drug effects Cholesterol / blood Coronary Angiography Coronary Artery Disease / drug therapy*, enzymology, physiopathology Double-Blind Method Enalapril / therapeutic use* Female Humans Lipid Metabolism Male Middle Aged Peptidyl-Dipeptidase A / metabolism Simvastatin / therapeutic use* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Angiotensin-Converting Enzyme Inhibitors; 0/Anticholesteremic Agents; 57-88-5/Cholesterol; 75847-73-3/Enalapril; 79902-63-9/Simvastatin; EC 3.4.15.1/Peptidyl-Dipeptidase A |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Functional effect of the C242T polymorphism in the NAD(P)H oxidase p22phox gene on vascular superoxi...
Next Document: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease: prim...